FierceBiotech

Salix Pharmaceuticals Announces Statistically Significant Results for Budesonide Foam in the Treatment of Active Mild to Moderate Ulcerative Proctitis or Ulcerative ...

<0> Salix Pharmaceuticals, Ltd.Adam C. DerbyshireExecutive Vice President and Chief Financial OfficerorG. Michael FreemanAssociate Vice President, Investor Relations and Corporate ...
Healio

FDA approves Padagis’ generic budesonide rectal foam for ulcerative colitis

Please provide your email address to receive an email when new articles are posted on . Padagis received FDA approval of its abbreviated new drug application for budesonide 2mg rectal foam for the ...
KELOLAND News

New Bausch Health Treatment PrUCERIS(R) (budesonide) Aerosol Foam Now Available Across Canada to Treat Mild to Moderate Distal Ulcerative Colitis in Adults

LAVAL, QE / ACCESSWIRE / September 12, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is pleased to announce that following its approval by Health Canada the new treatment Pr UCERIS ® ...
Monthly Prescribing Reference

Generic Version Uceris Rectal Foam Now Available

Credit: Getty Images. Padagis was granted 180 days of Competitive Generic Therapy exclusivity. A generic version of Uceris ® (budesonide 2mg rectal foam) has been made available by Padagis. Budesonide ...
Business Wire

Salix Announces Acceptance of NDA Filing For Budesonide Foam in Patients with Distal Ulcerative Colitis

RALEIGH, N.C.--(BUSINESS WIRE)--Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Food and Drug Administration (FDA) has accepted for filing a New Drug Application (NDA) for ...
Nasdaq

Bausch Health, Canada Inc. Announces Additional Public Drug Plan Listings for PrUCERIS(R) (Budesonide) Aerosol Foam To Treat Mild to Moderate Distal Ulcerative Colitis in Adults

LAVAL, QC / ACCESSWIRE / May 23, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced additional Canadian public drug plan listings for Pr ...
FOX8 Cleveland

Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to ...

UCERIS is now available for patients through the public drug plans of five Canadian provinces: Ontario, Quebec, Saskatchewan, New Brunswick and Nova Scotia. These first public drug plan listings for ...